RhumbLine Advisers
STSA

RhumbLine Advisers’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

RhumbLine Advisers’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,465
Closed -$272K – 3055
2020
Q2 		$272K Buy
+9,465
New +$219K ﹤0.01% 2624

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

RhumbLine Advisers's STSA Position: Q3 2020 in Review

RhumbLine Advisers sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2020, closing a stake of 9,465 shares — an estimated $272K sold.

RhumbLine Advisers first reported a position in STSA in Q2 2020 and held it in 1 quarter. The position peaked at $272K in Q2 2020. 46 funds tracked by Wall St. Rank hold STSA as of Q3 2020.

  • RhumbLine Advisers reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 9,465 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $272K.
  • RhumbLine Advisers first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • RhumbLine Advisers's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $272K in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on RhumbLine Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.